Skip to Content

Join the 'Jakafi' group to help and get support from people like you.

Jakafi News

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Lung Cancer, Colorectal Cancer, Isotretinoin, Rituxan, Claravis

Drugs Used in Cancer, Arthritis May Help Fight Hair Loss

Posted 23 Oct 2015 by Drugs.com

FRIDAY, Oct. 23, 2015 – Two drugs – one approved for use in arthritis and the other approved for cancer – may also hold potential for boosting hair growth, new animal research suggests. "The ultimate potential is a very effective topical product to rub on the scalp to help with all types of hair loss," said Dr. Luis Garza, an associate professor of dermatology at Johns Hopkins School of Medicine, who's familiar with the study findings. But he added, "More work needs to be done to translate these findings to a product which can be tested in a clinical trial on people." In the current study, researchers from Columbia University in New York City tested the drugs only on mice, including some with patches of human skin. If the medications work, it's not clear how much of the drugs may be needed for humans. It's also important to note that findings that look promising in animal research ... Read more

Related support groups: Rheumatoid Arthritis, Cancer, Alopecia, Xeljanz, Ruxolitinib, Diagnosis and Investigation, Jakafi, Tofacitinib

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Femara, Lupron Depot, Gleevec, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Rituxan

FDA Approves Jakafi (ruxolitinib) for Polycythemia Vera

Posted 4 Dec 2014 by Drugs.com

December 4, 2014 – The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition. Polycythemia vera occurs when too many red blood cells are made in the bone marrow. Patients may also experience an increase in white blood cells and platelets. An overabundance of blood cells can cause the spleen to swell, bleeding problems and blood clots in the veins near the skin surface (phlebitis). In addition, it puts patients at increased risk of stroke or heart attack. Jakafi’s new use is intended to treat polycythemia vera patients who have an inadequate response to or cannot tolerate hydroxyurea, another medicine often prescribed to reduce the number of red blood cells and platelets in the blood. Jakafi works by inhibiting e ... Read more

Related support groups: Polycythemia Vera, Ruxolitinib, Jakafi

Jakafi Approved for Chronic Bone Marrow Disease

Posted 4 Dec 2014 by Drugs.com

THURSDAY, Dec. 4, 2014 – Jakafi (ruxolitinib) has been approved by the U.S. Food and Drug Administration to treat polycythemia vera, a chronic disease of the bone marrow. Jakafi is the first FDA-sanctioned drug for the disease, which occurs when too many red blood cells are produced in the bone marrow. This may lead to a swollen spleen and phlebitis, characterized by blood clots near the surface of the skin. The disease also increases the risk of heart attack, the agency said Thursday in a news release. Jakafi has been approved for polycythemia vera patients who cannot tolerate or have an inadequate response to other drugs. In clinical studies involving 222 people, Jakafi's most common side effects included low counts of red blood cells and blood platelets, dizziness, constipation and shingles. The drug was first approved in 2011 to treat another bone marrow disorder, myelofibrosis. ... Read more

Related support groups: Polycythemia Vera, Jakafi

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by Drugs.com

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be dangerous," said study researcher Dr. Elina Jerschow, director of the Drug Allergy Center at Montefiore Medical Center and assistant professor of medicine at Albert Einstein College of Medicine, in New York City. While research from other countries has reported medications as a major culprit in anaphylaxis-related deaths, Jerschow said, the problem has been less defined in the United States. One reason is that there is no national registry for anaphylaxis deaths, she said. The study was ... Read more

Related support groups: Provera, Depo-Provera, Amoxicillin, Metronidazole, Doxycycline, Cephalexin, Clindamycin, Penicillin, Methotrexate, Azithromycin, Bactrim, Cipro, Ciprofloxacin, Accutane, Augmentin, Levaquin, Lupron, Flagyl, Keflex, Zithromax

Early Research With Drug Restores Hair in Patients With Alopecia

Posted 18 Aug 2014 by Drugs.com

SUNDAY, Aug. 17, 2014 – A drug used to treat a rare type of bone marrow cancer restores hair in patients with an autoimmune disease that causes hair loss, a new study found. Columbia University Medical Center researchers found that the drug ruxolitinib (brand name: Jakafi) restored hair growth in a small number of patients with alopecia areata, a disease in which immune cells destroy hair follicles. Alopecia areata can occur at any age and affects men and women. Patients typically lose patches of hair on the scalp, but may also lose facial and body hair. Currently, there are no known treatments to completely restore hair in these patients, who can suffer mental and emotional stress, the researchers said. First, the researchers identified the immune cells that destroy hair follicles in people with alopecia areata. They also discovered that ruxolitinib – which is approved by the U.S. ... Read more

Related support groups: Alopecia, Androgenetic Alopecia, Ruxolitinib, Jakafi

Cancer Chemotherapy Tied to Slight Rise in Risk for Leukemia

Posted 14 Feb 2013 by Drugs.com

THURSDAY, Feb. 14 – Chemotherapy can be a lifesaver for thousands of cancer patients, but a new study suggests that it might slightly raise the odds for a type of leukemia later in life. Over the past 30 years, the risk for acute myeloid leukemia (AML) has increased for patients who underwent chemotherapy for certain forms of cancer, particularly non-Hodgkin lymphoma, the new study found. On the other hand, the researchers from the U.S. National Cancer Institute said other cancer survivors may have a reduced risk for AML due to a change in chemotherapy agents that occurred decades ago. One expert not connected to the study stressed that cancer patients need to put the findings into perspective. "It's important to realize that the risk of developing acute myeloid leukemia related to prior chemotherapy is small and increases with the number of chemotherapy treatments given over time," ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Rituxan, Isotretinoin, Claravis, Votrient, Anastrozole, Tarceva

New Drug May Help Fight Rare Bone Marrow Disorder

Posted 29 Feb 2012 by Drugs.com

WEDNESDAY, Feb. 29 – Two new studies confirm that the new drug ruxolitinib can help people with the rare bone marrow disorder called myelofibrosis. While the drug, marketed in the United States under the brand name Jakafi, won't cure myelofibrosis, it can help ease symptoms, improve quality of life, and possibly improve survival according to the studies. "This is probably the most thrilling development I have seen in my career. The drug delivers rapid, durable benefit which makes a great difference to patients' lives," said the lead author of one of the studies, Dr. Claire Harrison, a consultant hematologist at Guy's Hospital in London. And, the lead author of the other study, Dr. Srdan Verstovsek, an associate professor in the leukemia department at the M.D. Anderson Cancer Center in Houston, said his team's study "shows that ruxolitinib provides a significant durable clinical benefit ... Read more

Related support groups: Myelofibrosis, Ruxolitinib, Jakafi

Ask a Question

Further Information

Related Condition Support Groups

Myelofibrosis, Myeloproliferative Disorders, Polycythemia Vera

Jakafi Patient Information at Drugs.com